Company News

Prof Aguzzi Joins our Clinical and Scientific Advisory Board

Published on September 9th, 2020

Cambridge, UK, September 10, 2020: Fluidic Analytics, a pioneer in protein interaction analysis, announced today the addition of Prof. Adriano Aguzzi to its Clinical and Scientific Advisory Board. Prof. Aguzzi is an internationally recognized expert in the field of neuropathology and the architect of multiple clinical research programs focusing on the effects of proteins and protein interactions on clinical outcomes.

“We are delighted to have Prof. Adriano Aguzzi, a renowned expert in the field of neuropathology, join our Clinical and Scientific Advisory Board,” said Andrew Lynn, Chief Executive Officer of Fluidic Analytics. “His deep understanding of the significance of protein interactions to key clinical challenges is a rare and valuable asset, while his passion to harness rigorous scientific insights to improve clinical practice is an inspiration to us all. We are thrilled to have Prof. Aguzzi help us shape the direction of our product roadmap and research activities to make the greatest possible contribution to medical science.”

Prof. Aguzzi is a physician, scientist and researcher who has served as Director of the Institute of Neuropathology at the University of Zurich (Zurich, Switzerland) since 1997. He spent more than 25 years studying the immunological and molecular basis of a range of neurodegenerative conditions including prion pathogenesis and neurodegenerative disorders such as Alzheimer’s disease. His more recent work includes a population-based study to map the antibody response to COVID-19 in the population of Zurich, Switzerland in the early stages of the pandemic.

The Clinical and Scientific Advisory Board will provide strategic guidance to Fluidic Analytics in its key areas of research and development with a particular focus on infectious diseases and neurology. It will support Fluidic Analytics’ management team on the scientific and clinical aspects of the Company’s development programs and its global scientific policy, including technology development, applications, partnerships, and market access. Prof. Adriano Aguzzi’s appointment to the Clinical and Scientific Advisory Board is the first to be announced by Fluidic Analytics.

Prof Adriano Aguzzi

Prof. Adriano Aguzzi the Director of the Institute of Neuropathology at the University of Zurich. He has devoted the past 25 years to studying the immunological and molecular basis of prion pathogenesis, combining transgenetics with molecular and immunological techniques to clarify the pathogenesis of the disease, and to identify cells and molecules involved in prion neuroinvasion. He is the Founder and Director of the Swiss National Reference Center for Prion Diseases and has developed diagnostic and therapeutic methods in the field of transmissible spongiform encephalopathies. He serves on the editorial board of Science and is the Editor in Chief of the Swiss Medical Weekly; he also serves on the scientific advisory board of philanthropic foundations and biomedical companies. Among other honors, Prof. Aguzzi has won the Ernst-Jung Prize, the Robert Koch Prize, and the medal of the European Molecular Biology Organization, and has held two ERC Advanced Grants.

About us

Fluidic Analytics – Understand the Machinery of Life

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionize the way proteins are characterized, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behavior transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterization and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit.

Receive our newsletter with our latest insights, webinars and news